Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abramson Cancer Center at Penn Medicine
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DLI Recipient
Relapsed AML or ALL ≥ 60 days after allogeneic SCT.
Evidence of residual donor chimerism on most recent analysis (within 4 weeks of enrollment).
Age ≥ 18 years of age,
Karnofsky performance status ≥ 60%.
Adequate organ function: Cr ≤ 2 mg/dL; ALT/AST \< 3x ULN, direct bili \<3x ULN.
Matched sibling or un-related donor (A, B, C, and DR) available to undergo leukopheresis.
Subjects must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.
Willing to provide blood samples for research purposes.
Willing to adhere to medically accepted form of birth control to prevent pregnancy (includes: complete abstention from intercourse, condoms, diaphragms, cervical cap, intra-uterine device, history of surgical sterility - tubal ligation or vasectomy in patient or partner, or oral contraceptive).
DLI Donor
1. HLA identical to recipient subject.
2. Considered medically eligible for leukopheresis procedure by independent donor physician (University of Pennsylvania physician who is not the recipient's primary transplant physician for related donors; physician designated by National Marrow Donor Program for unrelated donors).
3. Considered medically eligible to receive G-CSF (filgrastim) by independent donor physician.
You may not be if
Recipient
Prior cell therapy for relapse within the past 90 days.
Requirement for active immunosuppression to treat GVHD.
Pregnant or lactating women. The safety of this therapy on unborn children and effects on breast milk are not known.
Uncontrolled active infection
Any uncontrolled active medical disorder that would preclude participation as outlined.
Donor
\- Unable to participate in a leukopheresis procedure or receive G-CSF (filgrastim).